Literature DB >> 1862773

Non-Hodgkin's lymphomas of nasal cavity and paranasal sinuses. An immunohistochemical study.

E Campo1, A Cardesa, L Alos, A Palacin, J Cobarro, J Traserra, E Montserrat.   

Abstract

The authors studied the immunophenotype of nine sinonasal lymphomas using a panel of monoclonal antibodies that react with fixed, paraffin-embedded material (EMA, CAM 5.2, CD45, CD37 [MB-1], MB-2, L-26, CDw75 [LN-1], CD45RA [4 KB-5], CD43 [MT-1], and CD45RO [UCHL-1]). There were seven men and two women, with a mean age of 64 years (range, 9-89 years) and median age of 56 years. Three tumors were limited to the nasal cavity, and the other six had multiple sites of involvement, including the nasal cavity (five), antrum (six), ethmoid (two), orbit (two), and hard palate (one). Histologically, one was a lymphoblastic lymphoma (LBL), one was small cleaved-cell lymphoma (SCCL), three were mixed-cell lymphomas (MCLs), and four were large cell lymphomas (LCLs). Four cases were T-cell lymphomas (one SCCL, three MCLs), four were B-cell neoplasms (four LCLs), and one was of uncertain lineage (LBL). Angioinvasion, coagulative necrosis, and epitheliotropism were seen in the T-cell lymphomas. Extranasal dissemination was seen in four cases: one LBL that involved the lymph nodes, skin, and testes 15 months after diagnosis; one B-LCL that involved the skin 9 months after diagnosis; and one B-LCL and one T-MCL that involved the gastric mucosa and lung simultaneously with nasal presentation. This study shows a higher predominance of B-cell lymphomas in the sinonasal region than previously reported in Oriental populations. However, the T:B ratio of these lymphomas is still greater than that observed for primary lymph node-based neoplasms.

Entities:  

Mesh:

Year:  1991        PMID: 1862773     DOI: 10.1093/ajcp/96.2.184

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  11 in total

1.  Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.

Authors:  Ajay K Gopal; Stefano R Tarantolo; Naresh Bellam; Damian J Green; Melissa Griffin; Tatyana Feldman; Anthony R Mato; Amy J Eisenfeld; Scott C Stromatt; Andre Goy
Journal:  Invest New Drugs       Date:  2014-06-15       Impact factor: 3.850

Review 2.  Sinonasal tumors: a clinicopathologic update of selected tumors.

Authors:  Pieter J Slootweg; Alfio Ferlito; Antonio Cardesa; Lester D R Thompson; Jennifer L Hunt; Primož Strojan; Robert P Takes; Asterios Triantafyllou; Julia A Woolgar; Alessandra Rinaldo; Kenneth O Devaney; Leon Barnes
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-05-18       Impact factor: 2.503

3.  A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia.

Authors:  John C Byrd; John M Pagel; Farrukh T Awan; Andres Forero; Ian W Flinn; Delva P Deauna-Limayo; Stephen E Spurgeon; Leslie A Andritsos; Ajay K Gopal; John P Leonard; Amy J Eisenfeld; Jeannette E Bannink; Scott C Stromatt; Richard R Furman
Journal:  Blood       Date:  2013-12-31       Impact factor: 22.113

4.  Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.

Authors:  Xiaobin Zhao; Rosa Lapalombella; Trupti Joshi; Carolyn Cheney; Aruna Gowda; Martha S Hayden-Ledbetter; Peter R Baum; Thomas S Lin; David Jarjoura; Amy Lehman; Donna Kussewitt; Robert J Lee; Michael A Caligiuri; Susheela Tridandapani; Natarajan Muthusamy; John C Byrd
Journal:  Blood       Date:  2007-04-17       Impact factor: 22.113

5.  Epstein-Barr virus infection in sinonasal non-Hodgkin's lymphomas.

Authors:  P Luzi; L Leoncini; I Funtò; A Bruni; S Lazzi; L Pacenti; P Tosi
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

6.  Oral Lymphoma Prevalence in Iranian Population: A Multicenter Retrospective Study.

Authors:  Mohammad Esmaeil Akbari; Zahra Bastani; Sepideh Mokhtari; Saede Atarbashi Moghadam
Journal:  Iran J Cancer Prev       Date:  2015-12-23

7.  Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.

Authors:  Tadeusz Robak; Andrzej Hellmann; Janusz Kloczko; Javier Loscertales; Ewa Lech-Maranda; John M Pagel; Anthony Mato; John C Byrd; Farrukh T Awan; Holger Hebart; Jose A Garcia-Marco; Brian T Hill; Michael Hallek; Amy J Eisenfeld; Scott C Stromatt; Ulrich Jaeger
Journal:  Br J Haematol       Date:  2016-12-15       Impact factor: 6.998

8.  Unusual presentation of sporadic Burkitt's lymphoma originating from the nasal septum: a case report.

Authors:  Gaffar Aslan
Journal:  J Med Case Rep       Date:  2013-03-08

9.  L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma.

Authors:  Weiben Yong; Wen Zheng; Yuntao Zhang; Jun Zhu; Yan Wei; Deliang Zhu; Jiyou Li
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.319

10.  Expression of the metalloproteases MMP-1, MMP-2, MMP-3, MMP-9, MMP-11, TIMP-1 and TIMP-2 in angiocentric midfacial lymphomas.

Authors:  Abelardo Meneses-García; Alejandro Mohar Betancourt; Jorge Herrera Abarca; Adriana Becerril Montes; Lourdes Suarez Roa; Luz Ruíz-Godoy
Journal:  World J Surg Oncol       Date:  2008-10-27       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.